BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00346385 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Merkel Cell Carcinoma
SCLC

Interventions

DRUG: BB-10901

Sponsor

ImmunoGen, Inc.